MSPR.OTC.PinkMsp Recovery, INC

S-1/A: MSP Recovery Files Amendment for Resale of 9.9 Million Class A Shares

Sentiment:

S-1/A Filing


MSP Recovery has filed an amendment to its S-1 registration statement for the potential resale of up to 9,956,415 shares of Class A Common Stock by selling securityholders.

Capital raiseThe document mentions the potential for raising additional funds through the offering of debt or equity securities.The company relies on the Working Capital Credit Facility and the Yorkville SEPA as sources of liquidity.
Worse than expectedThe company has concluded that there is substantial doubt about its ability to continue as a going concern.The company is non-compliant with Nasdaq's bid price requirement.The company is under investigation by the SEC and the U.S. Attorneys Office.

Summary

  • MSP Recovery has filed an amendment to its S-1 registration statement for the potential resale of up to 9,956,415 shares of Class A Common Stock by selling securityholders.
  • The shares include those issuable upon exercise of warrants held by Virage Recovery Master, LP (VRM) and Virage Recovery Participation LP (VRP), as well as shares issued to Palantir Technologies, Inc.
  • The company will not receive any proceeds from the sale of these shares, except for nominal amounts if the VRM or VRP warrants are exercised, as the exercise price is only $0.0001 per share.
  • The document highlights the company's ongoing efforts to address its financial challenges, including amendments to credit facilities and agreements with Virage and Nomura.
  • It also mentions the company's non-compliance with Nasdaq listing requirements and the potential for a reverse stock split to regain compliance.
  • The company is still under investigation by the SEC and the U.S. Attorneys Office.

Sentiment

Score: 3

Explanation: The document presents a mixed sentiment. While there are some positive developments, such as settlements with P&C insurers, the overall tone is negative due to the company's financial challenges, regulatory scrutiny, and going concern uncertainty.

Positives

  • The company has reached settlements with several P&C insurers, including data sharing agreements and cash payments.
  • The company has extended the period to draw up to $23.3 million for working capital under the Working Capital Credit Facility.
  • The company has reduced the Floor Price under the Yorkville SEPA from $0.50 to $0.15, thereby curing the Floor Price Trigger.

Negatives

  • The company has concluded that there is substantial doubt about its ability to continue as a going concern.
  • The company is non-compliant with Nasdaq's bid price requirement.
  • The company is under investigation by the SEC and the U.S. Attorneys Office.
  • The company has a substantial amount of indebtedness and payment obligations.

Risks

  • The company's ability to continue as a going concern is uncertain.
  • The company may be delisted from Nasdaq if it does not regain compliance with listing requirements.
  • The company faces ongoing investigations by the SEC and the U.S. Attorneys Office.
  • The company has a substantial amount of indebtedness and payment obligations, which could adversely affect its ability to operate its business.
  • The company's recoveries may be limited due to legal restrictions.

Future Outlook

The company's future performance depends on its ability to generate substantial Claims recovery income and secure additional funding.

Industry Context

The document relates to the healthcare recovery and data analytics industry, specifically focusing on Medicare, Medicaid, and commercial insurance spaces. The company aims to disrupt the healthcare reimbursement system by identifying and recovering improper payments.

Comparison to Industry Standards

  • The document does not provide specific comparisons to industry standards or competitors.
  • However, it highlights the company's unique approach of receiving recovery rights through irrevocable assignments of Claims, which differs from competitors who provide services under third-party vendor contracts.
  • The document mentions that it would take any competitor a significant time to amass the portfolio of Claims rights currently owned by MSP Recovery due to the volume of Claims data and strength of data analytics.

Legal Proceedings

  • The company is under investigation by the SEC and the U.S. Attorneys Office.
  • The company is involved in litigation with Cano Health, LLC.

Related Party Transactions

  • The company has a loan agreement with John H. Ruiz and Frank C. Quesada.
  • The company has a legal services agreement with La Ley con John H. Ruiz P.A., d/b/a MSP Recovery Law Firm and MSP Law Firm, PLLC.
  • The company may make payments related to operational expenses on behalf of its affiliate, MSP Recovery Aviation, LLC.
  • The company has a note payable with Series MRCS.
  • The company has a relationship with VRM MSP.

Stakeholder Impact

  • Shareholders may experience dilution as a result of future equity offerings or the exercise of options and warrants.
  • The company's ability to operate its business and provide its solutions is dependent on its ability to attract and retain qualified employees.
  • General economic, political, and market forces beyond the company's control could reduce demand for its solutions.

Next Steps

  • The company intends to actively monitor its bid price and will consider available options to resolve the deficiency and regain compliance with the Nasdaq Listing Rules, including by effecting a reverse stock split, if necessary.
  • The company intends to fully cooperate with the SEC and the U.S. Attorneys Office in responding to the subpoenas.

Key Dates

DateDescription
May 20, 2022Date of Services Agreement between Virage Capital Management LP and MSP Recovery, LLC.
May 23, 2022Date of Business Combination between Lionheart Acquisition Corporation II and MSP Recovery, LLC.
November 13, 2023Date of Second Virage MTA Amendment, extending VRM Full Return payment due date to December 31, 2024.
January 1, 2024Effective date of Initial Virage Warrant.
March 1, 2024Date of comprehensive settlement with 28 affiliated property and casualty insurers (March 2024 Settlement).
March 26, 2024Date of Third Amended and Restated Nomura Promissory Note, extending maturity date to September 30, 2025.
April 1, 2024Date of Third Virage MTA Amendment, extending VRM Full Return payment due date to September 30, 2025.
April 18, 2024Date of comprehensive settlement with a separate group of affiliated P&C Insurers (April 2024 Settlement).
May 23, 2024Date of issuance of 500,000 shares of Class A Common Stock and VRP Warrant to Virage Recovery Participation LP.
June 7, 2024Date of notification from Nasdaq regarding non-compliance with bid price requirement.
June 30, 2024End of the reporting period for the Q2-2024 Quarterly Report.
July 16, 2024Date of comprehensive settlement with five affiliated P&C Insurers (July 2024 Settlement).
September 10, 2024Date of this prospectus.
December 4, 2024Deadline to regain compliance with Nasdaq's bid price requirement.

Keywords

Class A Common Stock, resale, warrants, Virage, Palantir, SEC investigation, Nasdaq compliance, going concern, debt, MSP Recovery

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.